Results 141 to 150 of about 15,432 (213)

Disease-Specific Differences in Pharmacokinetics of Paromomycin and Miltefosine Between Post-Kala-Azar Dermal Leishmaniasis and Visceral Leishmaniasis Patients in Eastern Africa. [PDF]

J Infect Dis
Chu WY, Verrest L, Younis BM, Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer K, Monnerat S, Wasunna M, Roseboom IC, Solomos A, Huitema ADR, Alves F, Dorlo TPC.   +14 more
europepmc   +1 more source

Drugs for 'neglected diseases': a bitter pill. [PDF]

, 2000
Pécoul, B, Veeken, H
core   +1 more source

Transfusion transmitted leishmaniasis. What to do with blood donors from endemic areas? [PDF]

, 2014
CASCIO, ANTONIO, MANSUETO, Pasquale, SEIDITA, Aurelio, Vitale, G   +3 more
core   +1 more source

VL-HIV co-infection with Leishmania containing skin lesions resembling para-kala-azar dermal leishmaniasis. [PDF]

PLoS Negl Trop Dis
Alves NO, Oshiro JA, Silva YC, Pacher GC, Casaril AE, Rizk YS, Uehara SNO, Paniago AMM, Andrade ILX, Arruda CCP, Oliveira AG.   +10 more
europepmc   +1 more source

Rising case-fatality rate of kala-azar (visceral leishmaniasis) in India: An unexpected challenge to the kala-azar elimination program?

Trop Parasitol
Mayilsamy M, Veeramanoharan R, Rajaiah P.   +2 more
europepmc   +1 more source

Monitoring the Long-Term Effectiveness of Miltefosine in Indian Post-Kala-Azar Dermal Leishmaniasis. [PDF]

Am J Trop Med Hyg
Roy S, Moulik S, Roy M, Ghosh MK, Chaudhuri SJ, Pandey DK, Jain S, Dagne DA, Chatterjee M.   +8 more
europepmc   +1 more source

A clinico-epidemiological study, assessing possible predictors of mortality and health-related quality of life for people living with visceral leishmaniasis - human immune virus (VL-HIV) co-infection in a high burden kala-azar endemic state of India: a descriptive cross-sectional study. [PDF]

BMC Infect Dis
Siddiqui NA, Pandey DK, Singh AK, Sinha SK, Ansari MZ, Kumar R, Pal B, Das VNR, Adhikary R, Jain S, Pandey K.   +10 more
europepmc   +1 more source

A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasis. [PDF]

Mol Ther Methods Clin Dev
Younis BM, Wiggins R, Khalil EAG, Osman M, Santoro F, Sonnati C, Keding A, Novedrati M, Montesi G, Noureldein A, Elmukashfi ETA, Mustafa AE, Alamin M, Saeed M, Salman K, Suliman AJ, Musa AEA, Layton AM, Lacey CJN, Kaye PM, Musa AM.   +20 more
europepmc   +1 more source

Combination Therapy for Post-Kala-Azar Dermal Leishmaniasis: A Literature Review of Current Evidence.

Indian J Dermatol
Kumari A, Siddiqui NA, Kumari S, Murti K, Kumar R, Pandey K, Padmakar S, Pal B.   +7 more
europepmc   +1 more source

Assessment of nutritional status among post-kala-azar dermal leishmaniasis patients in endemic areas of northern West Bengal, India.

Trop Parasitol
Samanta A, Patra D, Chaudhury A, Saha P, Sardar AA, Halder S, Maji AK, Guha SK, Das S.   +8 more
europepmc   +1 more source